Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048109 | 0.93 | ALK (0.65) | ALK | |
| SCHEMBL18589098 | 0.91 | ALK (0.51) | ALK | |
| SCHEMBL17048110 | 0.90 | ALK (0.63) | ALK | |
| SCHEMBL17054320 | 0.89 | ALK (0.73) | ALK | |
| SCHEMBL17048161 | 0.89 | ALK (0.66) | ALK | |
| SCHEMBL17048121 | 0.87 | ALK (0.66) | ALK | |
| SCHEMBL17048146 | 0.87 | ALK (0.78) | ALK | |
| SCHEMBL17054295 | 0.85 | ALK (0.64) | ALK | |
| SCHEMBL18589137 | 0.84 | ALK (0.52) | ALK | |
| SCHEMBL17048118 | 0.81 | ALK (0.77) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3110815-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | Jiangsu Ascentage Biomed Development Inc. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | ALK, BCL6, BCL6B | ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.